AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
195.61
+1.19 (+0.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close194.42
Open194.69
Bid194.08 x 800
Ask197.17 x 800
Day's Range193.72 - 196.28
52 Week Range163.31 - 201.23
Volume1,394,656
Avg. Volume2,773,006
Market Cap126.613B
Beta1.69
PE Ratio (TTM)58.60
EPS (TTM)3.34
Earnings DateOct 23, 2018 - Oct 29, 2018
Forward Dividend & Yield5.28 (2.69%)
Ex-Dividend Date2018-08-16
1y Target Est204.26
Trade prices are not sourced from all markets
  • 3 “Strong Buy” Stocks for the Week
    InvestorPlace14 hours ago

    3 “Strong Buy” Stocks for the Week

    Stocks entered the weekend on a sour note. Turkey currency woes were all the excuse needed to end the multi-day rally that had carried the S&P 500 within a whisker of all-time highs. But one day does not a downtrend make. My weekend scanning revealed many “strong buys” that deserve a top spots on your list of stocks to buy.

  • Amgen Inc (NASDAQ:AMGN): What You Have To Know Before Buying For The Upcoming Dividend
    Simply Wall St.16 hours ago

    Amgen Inc (NASDAQ:AMGN): What You Have To Know Before Buying For The Upcoming Dividend

    Attention dividend hunters! Amgen Inc (NASDAQ:AMGN) will be distributing its dividend of US$1.32 per share on the 07 September 2018, and will start trading ex-dividend in 2 days time onRead More...

  • What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
    Market Realist21 hours ago

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.

  • Investopedia4 days ago

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks4 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist5 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist5 days ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • Investor's Business Daily6 days ago

    Mylan Exploring Options As 'Unsustainable' Trends Hound Sales, Profit

    Mylan stock tumbled after the drugmaker missed second-quarter expectations, issued lagging guidance for 2018 and announced a strategic review.

  • Investopedia6 days ago

    Disney, Amgen Benefit From Shift to Value Stocks

    A change is coming to the stock market in which investors are beginning to favor value stocks over growth ones as the economy enters the late stages of its growth cycle. According to a report in  CNBC, citing Gina Sanchez, CEO of Chantico Global, signs are emerging that investors are looking at value stocks, which tend to be more of a defensive bet over their high-flying brethren in the growth camp. Growth stocks, namely tech ones, have been fueling the nine-year bull run in stocks, but with rising trade tensions and a widely held belief that earnings growth has or will soon peak, investors are setting their sights elsewhere.

  • 5 Companies Making Giant Buybacks
    InvestorPlace6 days ago

    5 Companies Making Giant Buybacks

    Thanks to the Republican tax plan and increasing revenues, investors are seeing a bit more green in their pockets. Momentum in iPhone sales, as well as record services revenues, helped the consumer tech giant realize a big jump in operating cash flows.

  • Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.
    Motley Fool6 days ago

    Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.

    Which of these dividend-paying biotech stocks is the better pick right now?

  • These Products Contributed to Pfizer’s Growth in Q2 2018
    Market Realist6 days ago

    These Products Contributed to Pfizer’s Growth in Q2 2018

    Pfizer’s (PFE) product portfolio includes both Innovative Health products and Essential Health products.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • Examining Pfizer’s Performance by Geography in Q2 2018
    Market Realist6 days ago

    Examining Pfizer’s Performance by Geography in Q2 2018

    Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.

  • Estimates and Recommendations for BeiGene on August 7
    Market Realist7 days ago

    Estimates and Recommendations for BeiGene on August 7

    BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.

  • CNBC7 days ago

    There's a big market shift coming and these stocks, including Disney, will benefit most

    A bull market powered by rocket fuel has sent growth stocks like Amazon AMZN and Netflix NFLX sky high for close to a decade. Now some market watchers are anticipating a change in the air. There are signs investors are beginning to favor value stocks, typically a defensive play, over riskier growth stocks, according to Gina Sanchez , CEO of Chantico Global.

  • Teva’s Granix Gets FDA Approval for Expanded Indication
    Market Realist7 days ago

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new vial presentation and indication in pediatric patients aged one month or older. Granix is a short-acting G-CSF (granulocyte colony-stimulating factor) that was approved by the FDA in 2012 for use in adults.

  • 3 Healthcare Stocks to Buy for the Sector Rebound
    InvestorPlace8 days ago

    3 Healthcare Stocks to Buy for the Sector Rebound

    Utilities, consumer staples and healthcare stocks all suffered under the onslaught of higher interest rates. Of the trio, Healthcare is the closest to reclaiming its prior peak. In fact, at $90, the Healthcare Sector SPDR Fund (NYSEARCA:XLV) is less than 2% away from record highs.

  • What Analysts Recommend for Mylan before Q2 2018 Earnings
    Market Realist8 days ago

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its second-quarter earnings results on August 8. In this part of the series, we’ll look at Wall Street analysts’ recent recommendations and 12-month target prices for Mylan.

  • Analysts Have Mixed Opinions about Ionis
    Market Realist8 days ago

    Analysts Have Mixed Opinions about Ionis

    What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.

  • Zacks Investment Ideas feature highlights: Merck and Amgen
    Zacks8 days ago

    Zacks Investment Ideas feature highlights: Merck and Amgen

    Zacks Investment Ideas feature highlights: Merck and Amgen

  • Teva Raises Its 2018 Guidance despite Missing Sales Estimate
    Market Realist8 days ago

    Teva Raises Its 2018 Guidance despite Missing Sales Estimate

    Teva Pharmaceutical Industries (TEVA) raised its fiscal 2018 guidance during its Q2 2018 earnings release yesterday, as it believes its restructuring plan is progressing well. Also, Copaxone has maintained its market share despite strong generic competition, the company’s net debt is lower, and its Austedo drug sales have been strong. Teva’s long-awaited migraine drug, Fremanezumab, which is expected to be a key growth driver once launched, is set to be reviewed by the FDA in September.

  • Analysts Raise Target Prices for TEVA after Its Q2 2018 Results
    Market Realist10 days ago

    Analysts Raise Target Prices for TEVA after Its Q2 2018 Results

    Teva Pharmaceutical Industries (TEVA) reported its Q2 2018 earnings results yesterday and updated its fiscal 2018 guidance. In this article, we’ll look at analysts’ recommendations for Teva stock for the next 12 months. Of the 28 analysts covering Teva stock, 15 (~54%) recommend “hold,” six (~21%) recommend “buy” or “strong buy,” and seven (25%) recommend “sell.”

  • What Pushed Teva’s Earnings Above Analysts’ Estimate
    Market Realist11 days ago

    What Pushed Teva’s Earnings Above Analysts’ Estimate

    Teva Pharmaceutical Industries (TEVA) reported its Q2 2018 earnings results yesterday, missing analysts’ sales estimates. However, it exceeded analysts’ adjusted diluted EPS estimate of $0.64, with non-GAAP adjusted diluted EPS of $0.78. Its GAAP diluted EPS were -$0.24.

  • 4 Trade Ideas for Amgen: Bonus Idea
    Yahoo Finance Contributors8 days ago

    4 Trade Ideas for Amgen: Bonus Idea